123 related articles for article (PubMed ID: 26117979)
1. Innovative therapy of ovarian cancer based on overexpression of CD44 receptor.
Bukowska B; Marczak A
Ginekol Pol; 2015 May; 86(5):388-91. PubMed ID: 26117979
[TBL] [Abstract][Full Text] [Related]
2. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2011 Jan; 12(2):1009-29. PubMed ID: 21541039
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
[TBL] [Abstract][Full Text] [Related]
4. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
[TBL] [Abstract][Full Text] [Related]
5. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
[TBL] [Abstract][Full Text] [Related]
7. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs.
Nascimento TL; Hillaireau H; Vergnaud J; Fattal E
Nanomedicine (Lond); 2016 Jul; 11(14):1865-87. PubMed ID: 27389568
[TBL] [Abstract][Full Text] [Related]
9. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
11. Advances in Hyaluronic Acid-Based Drug Delivery Systems.
Jiao Y; Pang X; Zhai G
Curr Drug Targets; 2016; 17(6):720-30. PubMed ID: 26028046
[TBL] [Abstract][Full Text] [Related]
12. Binding of ovarian cancer cells to immobilized hyaluronic acid.
Catterall JB; Gardner MJ; Jones LM; Turner GA
Glycoconj J; 1997 Nov; 14(7):867-9. PubMed ID: 9511993
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
14. Dual CD44 and folate receptor-targeted nanoparticles for cancer diagnosis and anticancer drug delivery.
Lee JY; Termsarasab U; Park JH; Lee SY; Ko SH; Shim JS; Chung SJ; Cho HJ; Kim DD
J Control Release; 2016 Aug; 236():38-46. PubMed ID: 27320169
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan magnetic nanoparticle for mitoxantrone delivery toward CD44-positive cancer cells.
Sargazi A; Shiri F; Keikha S; Majd MH
Colloids Surf B Biointerfaces; 2018 Nov; 171():150-158. PubMed ID: 30025377
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
17. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
19. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel.
Khayrani AC; Mahmud H; Oo AKK; Zahra MH; Oze M; Du J; Alam MJ; Afify SM; Quora HAA; Shigehiro T; Calle AS; Okada N; Seno A; Fujita K; Hamada H; Seno Y; Mandai T; Seno M
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]